[
  {
    "title": "Alert: Johnson Fistel Investigates Proposed Sale of MyoKardia; Is $225 a Fair Price? - Investing News Network",
    "title_detail": {
      "type": "text/plain",
      "language": null,
      "base": "",
      "value": "Alert: Johnson Fistel Investigates Proposed Sale of MyoKardia; Is $225 a Fair Price? - Investing News Network"
    },
    "links": [
      {
        "rel": "alternate",
        "type": "text/html",
        "href": "https://investingnews.com/news/biotech-investing/alert:-johnson-fistel-investigates-proposed-sale-of-myokardia-is-225-a-fair-price/"
      }
    ],
    "link": "https://investingnews.com/news/biotech-investing/alert:-johnson-fistel-investigates-proposed-sale-of-myokardia-is-225-a-fair-price/",
    "id": "52781102840921",
    "guidislink": false,
    "published": "Mon, 05 Oct 2020 13:39:15 GMT",
    "published_parsed": [
      2020,
      10,
      5,
      13,
      39,
      15,
      0,
      279,
      0
    ],
    "summary": "<ol><li><a href=\"https://investingnews.com/news/biotech-investing/alert:-johnson-fistel-investigates-proposed-sale-of-myokardia-is-225-a-fair-price/\" target=\"_blank\">Alert: Johnson Fistel Investigates Proposed Sale of MyoKardia; Is $225 a Fair Price?</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Investing News Network</font></li><li><a href=\"https://www.odwyerpr.com/story/public/14977/2020-10-05/w2o-works-media-for-myokardia.html\" target=\"_blank\">W2O Works Media for MyoKardia - Mon., Oct. 5, 2020</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">O'Dwyer's PR News</font></li><li><a href=\"https://www.detroitnews.com/story/business/2020/10/05/bristol-myers-buy-heart-drug-maker-13-billion/3621816001/\" target=\"_blank\">Bristol Myers to buy heart drug-maker for $13 billion</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">The Detroit News</font></li><li><a href=\"https://www.investors.com/news/technology/bmy-stock-dips-after-bristol-myers-squibb-reveals-another-big-acquisition/\" target=\"_blank\">BMY Stock Dips After Bristol Myers Squibb Reveals Another Big Acquisition</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Investor's Business Daily</font></li><li><a href=\"https://www.ibtimes.com/bristol-myers-squibb-agrees-buy-heart-drugmaker-myokardia-131-billion-cash-deal-3056943\" target=\"_blank\">Bristol Myers Squibb Agrees To Buy Heart Drugmaker MyoKardia In $13.1 Billion Cash Deal</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">International Business Times</font></li><li><strong><a href=\"https://news.google.com/stories/CAAqOQgKIjNDQklTSURvSmMzUnZjbmt0TXpZd1NoTUtFUWpaLUlyM2tJQU1FWS1ISEFTZVcwMVpLQUFQAQ?oc=5\" target=\"_blank\">View Full Coverage on Google News</a></strong></li></ol>",
    "summary_detail": {
      "type": "text/html",
      "language": null,
      "base": "",
      "value": "<ol><li><a href=\"https://investingnews.com/news/biotech-investing/alert:-johnson-fistel-investigates-proposed-sale-of-myokardia-is-225-a-fair-price/\" target=\"_blank\">Alert: Johnson Fistel Investigates Proposed Sale of MyoKardia; Is $225 a Fair Price?</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Investing News Network</font></li><li><a href=\"https://www.odwyerpr.com/story/public/14977/2020-10-05/w2o-works-media-for-myokardia.html\" target=\"_blank\">W2O Works Media for MyoKardia - Mon., Oct. 5, 2020</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">O'Dwyer's PR News</font></li><li><a href=\"https://www.detroitnews.com/story/business/2020/10/05/bristol-myers-buy-heart-drug-maker-13-billion/3621816001/\" target=\"_blank\">Bristol Myers to buy heart drug-maker for $13 billion</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">The Detroit News</font></li><li><a href=\"https://www.investors.com/news/technology/bmy-stock-dips-after-bristol-myers-squibb-reveals-another-big-acquisition/\" target=\"_blank\">BMY Stock Dips After Bristol Myers Squibb Reveals Another Big Acquisition</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Investor's Business Daily</font></li><li><a href=\"https://www.ibtimes.com/bristol-myers-squibb-agrees-buy-heart-drugmaker-myokardia-131-billion-cash-deal-3056943\" target=\"_blank\">Bristol Myers Squibb Agrees To Buy Heart Drugmaker MyoKardia In $13.1 Billion Cash Deal</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">International Business Times</font></li><li><strong><a href=\"https://news.google.com/stories/CAAqOQgKIjNDQklTSURvSmMzUnZjbmt0TXpZd1NoTUtFUWpaLUlyM2tJQU1FWS1ISEFTZVcwMVpLQUFQAQ?oc=5\" target=\"_blank\">View Full Coverage on Google News</a></strong></li></ol>"
    },
    "source": {
      "href": "https://investingnews.com",
      "title": "Investing News Network"
    },
    "sub_articles": [
      {
        "url": "https://investingnews.com/news/biotech-investing/alert:-johnson-fistel-investigates-proposed-sale-of-myokardia-is-225-a-fair-price/",
        "title": "Alert: Johnson Fistel Investigates Proposed Sale of MyoKardia; Is $225 a Fair Price?",
        "publisher": "Investing News Network"
      },
      {
        "url": "https://www.odwyerpr.com/story/public/14977/2020-10-05/w2o-works-media-for-myokardia.html",
        "title": "W2O Works Media for MyoKardia - Mon., Oct. 5, 2020",
        "publisher": "O'Dwyer's PR News"
      },
      {
        "url": "https://www.detroitnews.com/story/business/2020/10/05/bristol-myers-buy-heart-drug-maker-13-billion/3621816001/",
        "title": "Bristol Myers to buy heart drug-maker for $13 billion",
        "publisher": "The Detroit News"
      },
      {
        "url": "https://www.investors.com/news/technology/bmy-stock-dips-after-bristol-myers-squibb-reveals-another-big-acquisition/",
        "title": "BMY Stock Dips After Bristol Myers Squibb Reveals Another Big Acquisition",
        "publisher": "Investor's Business Daily"
      },
      {
        "url": "https://www.ibtimes.com/bristol-myers-squibb-agrees-buy-heart-drugmaker-myokardia-131-billion-cash-deal-3056943",
        "title": "Bristol Myers Squibb Agrees To Buy Heart Drugmaker MyoKardia In $13.1 Billion Cash Deal",
        "publisher": "International Business Times"
      }
    ]
  },
  {
    "title": "Is Myokardia Inc (MYOK) The Right Choice in Biotechnology? - InvestorsObserver",
    "title_detail": {
      "type": "text/plain",
      "language": null,
      "base": "",
      "value": "Is Myokardia Inc (MYOK) The Right Choice in Biotechnology? - InvestorsObserver"
    },
    "links": [
      {
        "rel": "alternate",
        "type": "text/html",
        "href": "https://www.investorsobserver.com/news/stock-update/is-myokardia-inc-myok-the-right-choice-in-biotechnology"
      }
    ],
    "link": "https://www.investorsobserver.com/news/stock-update/is-myokardia-inc-myok-the-right-choice-in-biotechnology",
    "id": "CBMia2h0dHBzOi8vd3d3LmludmVzdG9yc29ic2VydmVyLmNvbS9uZXdzL3N0b2NrLXVwZGF0ZS9pcy1teW9rYXJkaWEtaW5jLW15b2stdGhlLXJpZ2h0LWNob2ljZS1pbi1iaW90ZWNobm9sb2d50gFvaHR0cHM6Ly93d3cuaW52ZXN0b3Jzb2JzZXJ2ZXIuY29tL25ld3Mvc3RvY2stdXBkYXRlL2FtcC9pcy1teW9rYXJkaWEtaW5jLW15b2stdGhlLXJpZ2h0LWNob2ljZS1pbi1iaW90ZWNobm9sb2d5",
    "guidislink": false,
    "published": "Mon, 05 Oct 2020 13:57:57 GMT",
    "published_parsed": [
      2020,
      10,
      5,
      13,
      57,
      57,
      0,
      279,
      0
    ],
    "summary": "<a href=\"https://www.investorsobserver.com/news/stock-update/is-myokardia-inc-myok-the-right-choice-in-biotechnology\" target=\"_blank\">Is Myokardia Inc (MYOK) The Right Choice in Biotechnology?</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">InvestorsObserver</font>",
    "summary_detail": {
      "type": "text/html",
      "language": null,
      "base": "",
      "value": "<a href=\"https://www.investorsobserver.com/news/stock-update/is-myokardia-inc-myok-the-right-choice-in-biotechnology\" target=\"_blank\">Is Myokardia Inc (MYOK) The Right Choice in Biotechnology?</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">InvestorsObserver</font>"
    },
    "source": {
      "href": "https://www.investorsobserver.com",
      "title": "InvestorsObserver"
    },
    "sub_articles": []
  },
  {
    "title": "Bristol Myers Squibb buys biopharma MyoKardia for $13B - UPI News",
    "title_detail": {
      "type": "text/plain",
      "language": null,
      "base": "",
      "value": "Bristol Myers Squibb buys biopharma MyoKardia for $13B - UPI News"
    },
    "links": [
      {
        "rel": "alternate",
        "type": "text/html",
        "href": "https://www.upi.com/Top_News/US/2020/10/05/Bristol-Myers-Squibb-buys-biopharma-MyoKardia-for-13B/2021601902635/"
      }
    ],
    "link": "https://www.upi.com/Top_News/US/2020/10/05/Bristol-Myers-Squibb-buys-biopharma-MyoKardia-for-13B/2021601902635/",
    "id": "CAIiELa6Dz57uX4h78HPEnr308gqGAgEKg8IACoHCAowyrnjAjC42xswyM2eBg",
    "guidislink": false,
    "published": "Mon, 05 Oct 2020 13:43:16 GMT",
    "published_parsed": [
      2020,
      10,
      5,
      13,
      43,
      16,
      0,
      279,
      0
    ],
    "summary": "<a href=\"https://www.upi.com/Top_News/US/2020/10/05/Bristol-Myers-Squibb-buys-biopharma-MyoKardia-for-13B/2021601902635/\" target=\"_blank\">Bristol Myers Squibb buys biopharma MyoKardia for $13B</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">UPI News</font>",
    "summary_detail": {
      "type": "text/html",
      "language": null,
      "base": "",
      "value": "<a href=\"https://www.upi.com/Top_News/US/2020/10/05/Bristol-Myers-Squibb-buys-biopharma-MyoKardia-for-13B/2021601902635/\" target=\"_blank\">Bristol Myers Squibb buys biopharma MyoKardia for $13B</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">UPI News</font>"
    },
    "source": {
      "href": "https://www.upi.com",
      "title": "UPI News"
    },
    "sub_articles": []
  },
  {
    "title": "MyoKardia Shareholders Are Getting a Really Sweet Payday - 24/7 Wall St.",
    "title_detail": {
      "type": "text/plain",
      "language": null,
      "base": "",
      "value": "MyoKardia Shareholders Are Getting a Really Sweet Payday - 24/7 Wall St."
    },
    "links": [
      {
        "rel": "alternate",
        "type": "text/html",
        "href": "https://247wallst.com/healthcare-business/2020/10/05/myokardia-shareholders-are-getting-a-really-sweet-payday/"
      }
    ],
    "link": "https://247wallst.com/healthcare-business/2020/10/05/myokardia-shareholders-are-getting-a-really-sweet-payday/",
    "id": "CBMibmh0dHBzOi8vMjQ3d2FsbHN0LmNvbS9oZWFsdGhjYXJlLWJ1c2luZXNzLzIwMjAvMTAvMDUvbXlva2FyZGlhLXNoYXJlaG9sZGVycy1hcmUtZ2V0dGluZy1hLXJlYWxseS1zd2VldC1wYXlkYXkv0gFyaHR0cHM6Ly8yNDd3YWxsc3QuY29tL2hlYWx0aGNhcmUtYnVzaW5lc3MvMjAyMC8xMC8wNS9teW9rYXJkaWEtc2hhcmVob2xkZXJzLWFyZS1nZXR0aW5nLWEtcmVhbGx5LXN3ZWV0LXBheWRheS9hbXAv",
    "guidislink": false,
    "published": "Mon, 05 Oct 2020 14:07:56 GMT",
    "published_parsed": [
      2020,
      10,
      5,
      14,
      7,
      56,
      0,
      279,
      0
    ],
    "summary": "<a href=\"https://247wallst.com/healthcare-business/2020/10/05/myokardia-shareholders-are-getting-a-really-sweet-payday/\" target=\"_blank\">MyoKardia Shareholders Are Getting a Really Sweet Payday</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">24/7 Wall St.</font>",
    "summary_detail": {
      "type": "text/html",
      "language": null,
      "base": "",
      "value": "<a href=\"https://247wallst.com/healthcare-business/2020/10/05/myokardia-shareholders-are-getting-a-really-sweet-payday/\" target=\"_blank\">MyoKardia Shareholders Are Getting a Really Sweet Payday</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">24/7 Wall St.</font>"
    },
    "source": {
      "href": "https://247wallst.com",
      "title": "24/7 Wall St."
    },
    "sub_articles": []
  },
  {
    "title": "Wells Fargo & Company Downgrades Myokardia (NASDAQ:MYOK) to Equal Weight - MarketBeat",
    "title_detail": {
      "type": "text/plain",
      "language": null,
      "base": "",
      "value": "Wells Fargo & Company Downgrades Myokardia (NASDAQ:MYOK) to Equal Weight - MarketBeat"
    },
    "links": [
      {
        "rel": "alternate",
        "type": "text/html",
        "href": "https://www.marketbeat.com/instant-alerts/nasdaq-myok-a-buy-or-sell-right-now-2020-10/"
      }
    ],
    "link": "https://www.marketbeat.com/instant-alerts/nasdaq-myok-a-buy-or-sell-right-now-2020-10/",
    "id": "CBMiVmh0dHBzOi8vd3d3Lm1hcmtldGJlYXQuY29tL2luc3RhbnQtYWxlcnRzL25hc2RhcS1teW9rLWEtYnV5LW9yLXNlbGwtcmlnaHQtbm93LTIwMjAtMTAv0gFaaHR0cHM6Ly93d3cubWFya2V0YmVhdC5jb20vaW5zdGFudC1hbGVydHMvbmFzZGFxLW15b2stYS1idXktb3Itc2VsbC1yaWdodC1ub3ctMjAyMC0xMC9hbXAv",
    "guidislink": false,
    "published": "Mon, 05 Oct 2020 13:32:36 GMT",
    "published_parsed": [
      2020,
      10,
      5,
      13,
      32,
      36,
      0,
      279,
      0
    ],
    "summary": "<a href=\"https://www.marketbeat.com/instant-alerts/nasdaq-myok-a-buy-or-sell-right-now-2020-10/\" target=\"_blank\">Wells Fargo & Company Downgrades Myokardia (NASDAQ:MYOK) to Equal Weight</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">MarketBeat</font>",
    "summary_detail": {
      "type": "text/html",
      "language": null,
      "base": "",
      "value": "<a href=\"https://www.marketbeat.com/instant-alerts/nasdaq-myok-a-buy-or-sell-right-now-2020-10/\" target=\"_blank\">Wells Fargo & Company Downgrades Myokardia (NASDAQ:MYOK) to Equal Weight</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">MarketBeat</font>"
    },
    "source": {
      "href": "https://www.marketbeat.com",
      "title": "MarketBeat"
    },
    "sub_articles": []
  },
  {
    "title": "Global Stock Markets Climb on Hopes for Stimulus, President Donald Trump\u2019s Covid Health - Barron's",
    "title_detail": {
      "type": "text/plain",
      "language": null,
      "base": "",
      "value": "Global Stock Markets Climb on Hopes for Stimulus, President Donald Trump\u2019s Covid Health - Barron's"
    },
    "links": [
      {
        "rel": "alternate",
        "type": "text/html",
        "href": "https://www.barrons.com/articles/global-stocks-climb-on-hopes-over-stimulus-trump-health-51601889858"
      }
    ],
    "link": "https://www.barrons.com/articles/global-stocks-climb-on-hopes-over-stimulus-trump-health-51601889858",
    "id": "CBMiZGh0dHBzOi8vd3d3LmJhcnJvbnMuY29tL2FydGljbGVzL2dsb2JhbC1zdG9ja3MtY2xpbWItb24taG9wZXMtb3Zlci1zdGltdWx1cy10cnVtcC1oZWFsdGgtNTE2MDE4ODk4NTjSAWhodHRwczovL3d3dy5iYXJyb25zLmNvbS9hbXAvYXJ0aWNsZXMvZ2xvYmFsLXN0b2Nrcy1jbGltYi1vbi1ob3Blcy1vdmVyLXN0aW11bHVzLXRydW1wLWhlYWx0aC01MTYwMTg4OTg1OA",
    "guidislink": false,
    "published": "Mon, 05 Oct 2020 13:35:00 GMT",
    "published_parsed": [
      2020,
      10,
      5,
      13,
      35,
      0,
      0,
      279,
      0
    ],
    "summary": "<a href=\"https://www.barrons.com/articles/global-stocks-climb-on-hopes-over-stimulus-trump-health-51601889858\" target=\"_blank\">Global Stock Markets Climb on Hopes for Stimulus, President Donald Trump\u2019s Covid Health</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Barron's</font>",
    "summary_detail": {
      "type": "text/html",
      "language": null,
      "base": "",
      "value": "<a href=\"https://www.barrons.com/articles/global-stocks-climb-on-hopes-over-stimulus-trump-health-51601889858\" target=\"_blank\">Global Stock Markets Climb on Hopes for Stimulus, President Donald Trump\u2019s Covid Health</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Barron's</font>"
    },
    "source": {
      "href": "https://www.barrons.com",
      "title": "Barron's"
    },
    "sub_articles": []
  },
  {
    "title": "Harvard 'MacArthur genius' Kevin Eggan steps in to run early-stage research at rare disease specialist BioMarin - Endpoints News",
    "title_detail": {
      "type": "text/plain",
      "language": null,
      "base": "",
      "value": "Harvard 'MacArthur genius' Kevin Eggan steps in to run early-stage research at rare disease specialist BioMarin - Endpoints News"
    },
    "links": [
      {
        "rel": "alternate",
        "type": "text/html",
        "href": "https://endpts.com/harvard-macarthur-genius-kevin-eggan-steps-in-to-run-early-stage-research-at-rare-disease-specialist-biomarin/"
      }
    ],
    "link": "https://endpts.com/harvard-macarthur-genius-kevin-eggan-steps-in-to-run-early-stage-research-at-rare-disease-specialist-biomarin/",
    "id": "CBMigQFodHRwczovL2VuZHB0cy5jb20vaGFydmFyZC1tYWNhcnRodXItZ2VuaXVzLWtldmluLWVnZ2FuLXN0ZXBzLWluLXRvLXJ1bi1lYXJseS1zdGFnZS1yZXNlYXJjaC1hdC1yYXJlLWRpc2Vhc2Utc3BlY2lhbGlzdC1iaW9tYXJpbi_SAQA",
    "guidislink": false,
    "published": "Mon, 05 Oct 2020 13:45:59 GMT",
    "published_parsed": [
      2020,
      10,
      5,
      13,
      45,
      59,
      0,
      279,
      0
    ],
    "summary": "<a href=\"https://endpts.com/harvard-macarthur-genius-kevin-eggan-steps-in-to-run-early-stage-research-at-rare-disease-specialist-biomarin/\" target=\"_blank\">Harvard 'MacArthur genius' Kevin Eggan steps in to run early-stage research at rare disease specialist BioMarin</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Endpoints News</font>",
    "summary_detail": {
      "type": "text/html",
      "language": null,
      "base": "",
      "value": "<a href=\"https://endpts.com/harvard-macarthur-genius-kevin-eggan-steps-in-to-run-early-stage-research-at-rare-disease-specialist-biomarin/\" target=\"_blank\">Harvard 'MacArthur genius' Kevin Eggan steps in to run early-stage research at rare disease specialist BioMarin</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Endpoints News</font>"
    },
    "source": {
      "href": "https://endpts.com",
      "title": "Endpoints News"
    },
    "sub_articles": []
  },
  {
    "title": "The S&P 500 Was Down 4% in September. Keep Buying Anyway - Nasdaq",
    "title_detail": {
      "type": "text/plain",
      "language": null,
      "base": "",
      "value": "The S&P 500 Was Down 4% in September. Keep Buying Anyway - Nasdaq"
    },
    "links": [
      {
        "rel": "alternate",
        "type": "text/html",
        "href": "https://www.nasdaq.com/articles/the-sp-500-was-down-4-in-september.-keep-buying-anyway-2020-10-05"
      }
    ],
    "link": "https://www.nasdaq.com/articles/the-sp-500-was-down-4-in-september.-keep-buying-anyway-2020-10-05",
    "id": "CBMiYWh0dHBzOi8vd3d3Lm5hc2RhcS5jb20vYXJ0aWNsZXMvdGhlLXNwLTUwMC13YXMtZG93bi00LWluLXNlcHRlbWJlci4ta2VlcC1idXlpbmctYW55d2F5LTIwMjAtMTAtMDXSAWVodHRwczovL3d3dy5uYXNkYXEuY29tL2FydGljbGVzL3RoZS1zcC01MDAtd2FzLWRvd24tNC1pbi1zZXB0ZW1iZXIuLWtlZXAtYnV5aW5nLWFueXdheS0yMDIwLTEwLTA1P2FtcA",
    "guidislink": false,
    "published": "Mon, 05 Oct 2020 13:33:00 GMT",
    "published_parsed": [
      2020,
      10,
      5,
      13,
      33,
      0,
      0,
      279,
      0
    ],
    "summary": "<a href=\"https://www.nasdaq.com/articles/the-sp-500-was-down-4-in-september.-keep-buying-anyway-2020-10-05\" target=\"_blank\">The S&P 500 Was Down 4% in September. Keep Buying Anyway</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Nasdaq</font>",
    "summary_detail": {
      "type": "text/html",
      "language": null,
      "base": "",
      "value": "<a href=\"https://www.nasdaq.com/articles/the-sp-500-was-down-4-in-september.-keep-buying-anyway-2020-10-05\" target=\"_blank\">The S&P 500 Was Down 4% in September. Keep Buying Anyway</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Nasdaq</font>"
    },
    "source": {
      "href": "https://www.nasdaq.com",
      "title": "Nasdaq"
    },
    "sub_articles": []
  },
  {
    "title": "Dow Climbs 200 Points While DraftKings Slumps And Bristol Myers, BridgeBio Pharma Announce Acquisitions - Forbes",
    "title_detail": {
      "type": "text/plain",
      "language": null,
      "base": "",
      "value": "Dow Climbs 200 Points While DraftKings Slumps And Bristol Myers, BridgeBio Pharma Announce Acquisitions - Forbes"
    },
    "links": [
      {
        "rel": "alternate",
        "type": "text/html",
        "href": "https://www.forbes.com/sites/jonathanponciano/2020/10/05/dow-climbs-200-points-draftkings-slumps-and-bristol-myers-bridgebio-pharma-announce-acquisitions/"
      }
    ],
    "link": "https://www.forbes.com/sites/jonathanponciano/2020/10/05/dow-climbs-200-points-draftkings-slumps-and-bristol-myers-bridgebio-pharma-announce-acquisitions/",
    "id": "CAIiEL69UgTi34sPtGwNOiru54EqFQgEKg0IACoGCAowrqkBMKBFMLKAAg",
    "guidislink": false,
    "published": "Mon, 05 Oct 2020 13:55:03 GMT",
    "published_parsed": [
      2020,
      10,
      5,
      13,
      55,
      3,
      0,
      279,
      0
    ],
    "summary": "<a href=\"https://www.forbes.com/sites/jonathanponciano/2020/10/05/dow-climbs-200-points-draftkings-slumps-and-bristol-myers-bridgebio-pharma-announce-acquisitions/\" target=\"_blank\">Dow Climbs 200 Points While DraftKings Slumps And Bristol Myers, BridgeBio Pharma Announce Acquisitions</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Forbes</font>",
    "summary_detail": {
      "type": "text/html",
      "language": null,
      "base": "",
      "value": "<a href=\"https://www.forbes.com/sites/jonathanponciano/2020/10/05/dow-climbs-200-points-draftkings-slumps-and-bristol-myers-bridgebio-pharma-announce-acquisitions/\" target=\"_blank\">Dow Climbs 200 Points While DraftKings Slumps And Bristol Myers, BridgeBio Pharma Announce Acquisitions</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Forbes</font>"
    },
    "source": {
      "href": "https://www.forbes.com",
      "title": "Forbes"
    },
    "sub_articles": []
  },
  {
    "title": "US Stocks Open Higher on Muted Signs of Ebbing Political Risk - Marketscreener.com",
    "title_detail": {
      "type": "text/plain",
      "language": null,
      "base": "",
      "value": "US Stocks Open Higher on Muted Signs of Ebbing Political Risk - Marketscreener.com"
    },
    "links": [
      {
        "rel": "alternate",
        "type": "text/html",
        "href": "https://www.marketscreener.com/news/latest/U-S-Stocks-Open-Higher-on-Muted-Signs-of-Ebbing-Political-Risk--31484077/"
      }
    ],
    "link": "https://www.marketscreener.com/news/latest/U-S-Stocks-Open-Higher-on-Muted-Signs-of-Ebbing-Political-Risk--31484077/",
    "id": "CAIiEIqGmi39e7h_eqIO1rG7T_4qGQgEKhAIACoHCAowxZ6VCzC-_6oDMMvTxQY",
    "guidislink": false,
    "published": "Mon, 05 Oct 2020 13:49:38 GMT",
    "published_parsed": [
      2020,
      10,
      5,
      13,
      49,
      38,
      0,
      279,
      0
    ],
    "summary": "<a href=\"https://www.marketscreener.com/news/latest/U-S-Stocks-Open-Higher-on-Muted-Signs-of-Ebbing-Political-Risk--31484077/\" target=\"_blank\">US Stocks Open Higher on Muted Signs of Ebbing Political Risk</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Marketscreener.com</font>",
    "summary_detail": {
      "type": "text/html",
      "language": null,
      "base": "",
      "value": "<a href=\"https://www.marketscreener.com/news/latest/U-S-Stocks-Open-Higher-on-Muted-Signs-of-Ebbing-Political-Risk--31484077/\" target=\"_blank\">US Stocks Open Higher on Muted Signs of Ebbing Political Risk</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Marketscreener.com</font>"
    },
    "source": {
      "href": "https://www.marketscreener.com",
      "title": "Marketscreener.com"
    },
    "sub_articles": []
  }
]